GSK-208136/014 (MeMuRu-OKA-014)

Study to evaluate immunogenicity and safety of one dose of GSK Biologicals' combined measles-mumps-rubella-varicella vaccine given to healthy children previously primed with one dose of measles-mumps-rubella vaccine in their second year of life and presumed seronegative for varicella
Combined Measles, Mumps, Rubella, Varicella Vaccine
208136/014 (MeMuRu-OKA-014)
Measles; Mumps; Rubella; Varicella
Phase 3
An annotated case report form is not available. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
October 2015